NCT06112379 2026-04-02
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
NCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04193059 2025-11-26
PANSY
Fudan University
Phase 3 Active not recruiting
NCT03515798 2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2 Active not recruiting
NCT04335669 2025-09-12
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
Phase 3 Active not recruiting
NCT00005584 2025-08-05
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT02455141 2025-07-11
TCTN
Shanghai Jiao Tong University School of Medicine
Phase 3 Active not recruiting
NCT03725059 2025-07-11
KEYNOTE-756
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting